The Impact of Treatment with Guselkumab on Skin-related Quality of Life in Male and Female Patients with Moderate to Severe Psoriasis: Results from the VOYAGE 1 and 2 Trials

被引：0

作者：

Armstrong, April ^{[1
]}

Puig, Luis ^{[2
]}

Papp, Kim A. ^{[3
]}

Strauss, Marcie E. ^{[4
]}

Yang, Ya-Wen ^{[5
]}

Cheng, Ru-Fong ^{[6
]}

Miller, Megan ^{[7
]}

Murase, Jenny E. ^{[8
,9
]}

Fernandez-Penas, Pablo ^{[10
]}

Han, Chenglong ^{[11
]}

机构：

[1] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA

[2] Autonomous Univ Barcelona, Hosp Santa Creu & Sant Pau, Barcelona, Spain

[3] K Papp Clin Res & Prob Res Inc, Waterloo, ON, Canada

[4] MEDASOURCE, Indianapolis, IN USA

[5] Janssen Pharmaceut Co Johnson & Johnson, Immunol Global Med Affairs, Horsham, PA USA

[6] Johnson & Johnson, Womens Hlth, Chief Med Off, New Brunswick, NJ USA

[7] Janssen Res & Dev LLC, Spring House, PA USA

[8] Univ Calif San Francisco, San Francisco, CA USA

[9] Palo Alto Fdn Med Grp, Mountain View, CA USA

[10] Westmead Hosp, Sydney Med Sch, Dept Dermatol, Westmead, NSW, Australia

[11] Janssen Global Serv LLC, Malvern, PA USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：AB235 / AB235

页数：1

共 50 条

[31] Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: Results from the phase 3 VOYAGE 1 study
Blauvelt, Andrew
Papp, Kim
Griffiths, Christopher E. M.
Randazzo, Bruce
Wasfi, Yasmine
Shen, Yaung-Kaung
Kimball, Alexa B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB120 - AB120
[32] Sustained improvement in general health-related quality life and work productivity in patients with moderate to severe psoriasis treated with guselkumab: 3-year data from clinical trial VOYAGE 2
Reich, K.
Gordon, K. B.
Foley, P.
Lomaga, M.
Han, C.
Song, M.
Shen, Y. -K.
Radtke, M. A.
Wu, J. J.
Armstrong, A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB280 - AB280
[33] Sustained improvement in general health-related quality of life and work productivity in patients with moderate to severe psoriasis treated with guselkumab: 5-year data from clinical trial VOYAGE 2
Reich, Kristian
Gordon, Kenneth B.
Foley, Peter
Lomaga, Mark
Han, Chenglong
Miller, Megan
You, Yin
Radtke, Marc Alexander
Wu, Jashin J.
Armstrong, April W.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB174 - AB174
[34] EFFICACY RESPONSES ACROSS DISEASE SEVERITY AND TREATMENT HISTORY SUBGROUPS OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS TREATED WITH GUSELKUMAB: POOLED RESULTS FROM VOYAGE-1 AND VOYAGE-2 THROUGH 5 YEARS
Gordon, K.
Merola, J. F.
Foley, P.
Choi, O.
Chan, D.
Miller, M.
You, Y.
Shen, Y. K.
Yang, Y. W.
Blauvelt, A.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1842 - 1842
[35] Association between skin-related quality of life and race in patients with moderate-to-severe hidradenitis suppurativa: Analysis of two phase 3 clinical trials
Midgette, Bria
Strunk, Andrew
Garg, Amit
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (06) : 1247 - 1250
[36] Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years
Griffiths, Christopher E. M.
Papp, Kim A.
Kimball, Alexa B.
Randazzo, Bruce
Song, Michael
Li, Shu
Shen, Yaung-Kaung
Blauvelt, Andrew
JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (08) : 826 - 832
[37] Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: Results from the phase 3-VOYAGE 1 study
Blauvelt, A.
Papp, K.
Griffiths, C. E. M.
Randazzo, B.
Wasfi, Y.
Shen, Y.
Li, S.
Kimball, A. B.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 40 - 40
[38] Social relationships, sexual difficulty, and the impact of treatment with guselkumab versus adalimumab in men and women with psoriasis: Results from VOYAGE 1 and 2
Armstrong, April
Liu, Yi-hsuan
Yang, Ya-Wen
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB112 - AB112
[39] Long-term safety of guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment
Blauvelt, Andrew
Gordon, Kenneth B.
Griffiths, Christopher E. M.
Papp, Kim A.
Foley, Peter
Song, Michael
Miller, Megan
Shen, Yaung-Kaung
You, Yin
Ramachandran, Paraneedharan
Reich, Kristian
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB174 - AB174
[40] Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab
Reich, Kristian
Foley, Peter
Han, Chenglong
McElligott, Sean
Muser, Erik
Li, Nan
Armstrong, April W.
JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (06) : 617 - 623

← 1 2 3 4 5 →